Inhibitory Effect of Abitylguanide on Adenovirus Replication

Angel S. Galabov; Vesselina Vassileva; Vera Karabasheva

doi:10.1055/s-0043-111014

Drug Research, Table of Contents

Drug Res (Stuttg) 2017; 67(10): 583-590
DOI: 10.1055/s-0043-111014

Original Article

Inhibitory Effect of Abitylguanide on Adenovirus Replication

Angel S. Galabov

¹Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia

,

Vesselina Vassileva

²Electron microscopy, Medical Academy, Sofia, Bulgaria

,

Vera Karabasheva

²Electron microscopy, Medical Academy, Sofia, Bulgaria

› Author Affiliations

Abstract

N’N’-anhydro-bis(β-hydroxy-ethyl)biguanide.HCl (abitylguanide) demonstrated a marked inhibitory effect on replication in cell cultures of a broad spectrum of human adenoviruses both standard laboratory strains and strains isolated from epidemic keratoconjunctivitis patients. The strongest inhibitory activity was found in viruses belonging to subgroup C (Rosen’s subgroup III). The compound susceptible period of human adenovirus 5 replication in primary cell cultures of human embryo kidney cells included the total replication cycle and was especially pronounced during the exponential phase of the virus growth curve. Electron microscopy established that the compound decreased the percentage of cells in which mature or empty virions with the characteristic nuclear localization were observed; a complete absence of paracrystals was registered and the number of cells with virus particles arranged in crystals in the nucleoplasm was strongly decreased. Abitylguanide can be considered as a ligand of adenovirus capsid protein(s).

Key words

abitylguanide - human adenoviruses - electron microscopy

Full Text

References

References
1 Wadell G, Allard A, Johansson M. et al. Enteric adenoviruses. Ciba Foundation Symposium. 1987; 128: 63-91
2 Liu L, Qian Y, Zhang Y. et al. Adenoviruses associated with acute diarrhea in children in Beijing, China. PLoS One 2014; 9: e88791
3 Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008; 21: 704-715
4 Jin X, Ishiko H, Nata NT. Molecular epidemiology of adenoviral conjunctivitis in Hanoi, Vietnam. Am J Ophthalmol 2006; 113: 1064-1066
5 Butt AL, Chodosh J. Adenoviral keratoconjunctivitis in a tertiary care eye clinic. Cornea 2006; 25: 199-202
6 Sambursky RP, Fram N, Cohen EJ. The prevalence of adenoviral conjunctivitis at the Wille Eye Hospital emergency room. Optometry 2007; 78: 236-239
7 Bialansiewicz A. Adenoviral keratoconjunctivitis. Sultan Qaboos Univ Med J 2007; 7: 15-23
8 Pihos AM. Epidemic keratoconjunctivitis: A review of current concepts in management. J Optom 2013; 6: 69-74
9 Tabbara KF, Jarade EF. Ganciclovir effects in adenoviral keratoconjunctivitis. [abstracts 3111-B253] ARVO 2001; 42: S579
10 Kinchington PR, Romanowski EG, Gordon YJ. Prospects for adenovirus antivirals. J Antimicrob Chemother 2005; 55: 424-429
11 Throusdale MD, Goldschmidt PL, Nobrega R. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea 1994; 13: 435-439
12 Isenberg SJ, Apt L, Valenton M. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol 2002; 134: 681-688
13 de Oliveira CB, Stevenson D, LaBree L. et al. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res 1996; 31: 165-172
14 Romanowski EG, Gordon YI. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalm & Vis Sci 2000; 41: 460-463
15 Hillenkamp J, Reinhard T, Ross RS. et al. The effect of cidofovir 1% with and without cyclosporine a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: A controlled clinical pilot study. Ophthalmology 2002; 109: 845-850
16 Greber UF, Arnberg N, Wadel N. et al. Adenoviruses: From pathogens to therapeutics. 10th International Adenovirus Meeting. Cellular Microbiology 2013; 15: 16-23
17 Öberg CT, Strand M, Andersson EK. et al. Synthesis, biological evaluation and structure-activity relationship of 2-[2-(benzoylamino)benzoylamino] benzoic acid analogues as inhibitors of adenovirus replication. J Medic Chemistry 2012; 55: 3170-3181
18 Galabov A, Vilaginès R. Action du chlorhydrate de N’N’anhydro-bis (β-hydroxy-ethyl) biguanide (ABOB) sur le développement du virus de l’herpès en culture de tissu. Arch Ges Virusforsch 1970; 31: 183-190
19 Galabov A, Vilaginès R. Action of N’N’anhydrobis (β-hydroxyethyl) biguanide (ABOB) on the DNA synthesis of herpes simplex virus. C r Acad Bulg Sci 1971; 24: 119-121
20 Rénard G, Dhermy P. Étude clinique et expérimentales de l’herpès de la cornée et de son traitement par un virostatique nouveau ABOB (Virustat). Sém Hôp (Paris) 1963; 39: 1250
21 Galabov AS. N,N’-Disubstituted thioureas and abitylguanide – specific viral inhibitors. DSc Dissertation These, Medical Academy, Sofia. 1978;
22 Duluc J, Labouche F. Premiers résultats obtenues dans le traitement de quelques dermatoses par le 1022 Y. D, (ABOB). Bull Soc Franc Dermat & Sypb 1962; 69: 539
23 Rivoire MJ. Action du chlorhydrate de N’N’ anhydro-bis (β-hydroxyethyl) biguanide sur certaines affections dermatologiques d’origine virale. Lyon Médical 1965; 6: 323
24 Longchamps J. A propos de quelques résultats cliniques d’un nouveau médicament anti-viral. Journ Méd Chir Prat 1963; 134: 107
25 Sjöberg B. Experiments on prophylaxis and suppression of epidemic influenza with N’N’-anhydrobis-(β-hydroxyethyl)biguanide-hydrochloride (ABOB). A double blind study. Antib Med Clin Therapy 1960; 7: 97-102
26 Cutting WC. Antifertility effects of biguanides. Antibiot & Chemotherapy (Northfield) 1962; 12: 671-675
27 Wassileva PIv, Galabov AS. Über die Behandlung der epidemischen Keratokonjunktivitis mit ABOB. Klinische und Laboruntersuchungen. Klin Mbl Augenheilk 1975; 166: 77-83
28 Vassileva P, Galabov AS. Combined therapy of epidemic keratoconjunctivitis. In: Bialasiewicz A. (ed.) Update of infectious diseases of the eye. New York: Springer Verlag; 1993: 307-314
29 Galabov BS, Lozanova HS, Galabov AS. Method for obtaining of N’N’anhydrobis (β-hydroxyethyl) biguanide hydrochloride. Bulgarian Iinvention Certificate No. 41554, reg. No 74436/8.04.1986; transformed in Patent No 341/24.02.1994.
30 Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27: 493-497
31 Millonig G. Advantages of a phosphate buffer for OsO₄ solutions in fixation. J. Appl Phys 1961; 32: 1637
32 Reynolds ES. The use of lead citrate at a high pH as an electron-opaque strain in electron microscopy. J Cell Biol 1963; 17: 208-212
33 Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance. Eur J. Microbiol Immunol (Bp) 2014; 4: 26-33
34 Rosen L. A hemagglutination-inhibition technique for typing adenoviruses. Amer J Hyg 1960; 71: 120-128
35 Norrby E, Wadell C. Soluble components of adenovirus type 4. Virology 1967; 31: 592-600
36 Morgan C, Godman GC, Rose HM. et al. Electron microscopic and histochemical studies of an usual crystalline protein occurring in cells infected by type 5 adenovirus. Preliminary observation. J Biophys Biochem Cytol 1957; 3: 505-508
37 Morgan C, Godman GD, Breittenfeld PM. et al. A correlative study by electron and light microscopy of the development of type 5 adenovirus. I. Electron microscopy. J Exp Med 1960; 112: 373-381
38 Martinez-Palomo A, Le Bois J, Bernhard W. Electron microscopy of adenovirus 12 replication.1. Fine structural changes in the nucleus in infected KB cells. J Virol 1967; 1: 817-829
39 Franqueville L, Henning P, Magnusson M. et al. Protein crystals in adenovirus type 5-infected cells : requirements for intranuclearcrystallogenesis, structural and functionalanalysis. PLoS One 2008;
40 Torpier G, Petitprez A. Étude ultrastructurals de paracrystaux protéiques intranucléaires induits par adénovirus 5. Journ Microscopie 1968; 7: 411
41 Weber J, Stich HF. Electron microscopy of cells infected with adenovirus type 2. J Virol 1969; 3: 198-204
42 Boulanger PA, Torpier G, Biserte G. Investigation on intranuclear paracrystalline inclusions induced by adenoviruys 5 in KB cells. J gen Virol 1971; 6: 329-332
43 Boulanger PA, Puvion F. Large-scale preparation of soluble adenovirus hexon, penton and fiber antigens in highly purified form. Eur J Biochem 1973; 39: 37-42
44 Wills EJ, Russel WC, Williams JF. Adenovirus-induced crystals: studies with temperature-sensitive mutants. J gen Virol 1973; 20: 407-412
45 Henry CJ, Atchison RW. Paracrystal formation in cell cultures infected with adenovirus type 2. J Virol 1971; 8: 842-849
46 Henry CJ, Slifkin M, Merkow LP. et al. The ultrastructure and nature of adenovirus type 2-induced paracrystalline formation. Virol 1971; 44: 215-218
47 Marusyk R, Norby E, Marusyk H. The relationship of adenovirus-induced paracrystalline structures to the virus core protein(s). J gen Virol 1972; 14: 261-270
48 Carstens EB, Marusyk RG. Crystallization and reaggregation of adenovirus type 5 structural components from infected cell extracts. J gen Virol 1977; 34: 541-545
49 Weber J. Physical mapping of the genes controlling adenovirus paracrystal formation. Canadian J Microbiol 1978; 24: 1381-1386
50 Wodrich H, Guan T, Cingolani G. et al. Switch from capsid protein import to adenovirus assembly by cleavage of nuclear transport signals. EMBO J 2003; 22: 6245-6255